Oura Health Inc Confidentially Files for IPO Marking Milestone for Wearable Tech Sector Trump Pressures Bank of America JPMorgan on Alleged Conservative Debanking Trump Rejects Iran Counterproposal Prolonging Strait of Hormuz Standoff and Energy Market Volatility BofA Issues Cautious Assessment on Deckers DECK PostEarnings Outlook Singapore Targets Faster Private Banking Account Opening to Boost Wealth Hub Status Goldman Sachs Reportedly Tapped to Lead SpaceX IPO in Potentially Historic Market Debut HWC Q1 2026 Earnings Modest EPS Beat Amid Stable Operating Environment HYPR Q1 2026 Earnings Narrower Loss Exceeds Estimates as Commercialization Efforts Continue BW Q1 2026 Earnings Significant EPS Miss Sends Shares Lower GIII Q1 2026 Earnings EPS Misses Estimates as Apparel Group Faces Margin Pressure Silicom Ltd SILC Q1 2026 Earnings EPS Beat Despite Loss Stock Rises on NarrowerThanExpected Loss KFS Q1 2026 Earnings Reports Net Loss Amid Limited Financial Disclosures Amylyx Pharmaceuticals AMLX Gains 344 as Biotech Sentiment Lifts Shares Infobird IFBD Shares Plunge Nearly 20 Testing Critical Support at 080 Forte Biosciences Inc FBRX Edges Lower as Key Support Holds in Focus LendingTree Holds Above Support After Modest Gain Saba Capital Income Opportunities Fund II SABA Holds Steady Near Support Amid Low Volatility Synopsys Appoints Elliott Management Partner Jesse Cohn to Board of Directors DCBO Q1 2026 Earnings EPS Misses Estimates by a Slim Margin Stock Slips Slightly Art Technology Acquisition Warrants ARTCW Rally 606 to 035 Testing Key Resistance HPP Q1 2026 Earnings Surprise Beat on EPS Amid Persistent Office Market Headwinds OrthoPediatrics Corp KIDS Q1 2026 Earnings NarrowerThanExpected Loss Fails to Lift Shares Guidewire Software GWRE Q1 2026 Earnings Strong EPS Beat Drives Positive Market Sentiment KKR Q1 2026 Earnings EPS Beats Estimates Stock Edges Lower OII Q1 2026 Earnings EPS Surpasses Estimates by 1156 Damora Therapeutics Q1 2026 Earnings WiderThanExpected Loss Despite Stock Gain OKUR Q1 2026 Earnings Wider EPS Loss Underscores Heavy RD Investment as PreRevenue Biotech Advances Pipeline